Anti-CD20 antibody-related pyoderma gangrenosum

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2016卷 / 1期

关键词：

D O I：

10.1007/s40278-024-62495-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[1] Anti-CD20 monoclonal antibodies, low risk of pyoderma gangrenosum
Reactions Weekly, 2025, 2043 (1) : 1 - 1
[2] Anti-CD20 monoclonal antibody in autoimmune diseases
Pogliani, EM
Larocca, A
BIOMEDICINE & PHARMACOTHERAPY, 2002, 56 (07) : 350 - 351
[3] Ofatumumab, a human anti-CD20 monoclonal antibody
Osterborg, Anders
EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (03) : 439 - 449
[4] Anti-CD20 antibody wows in multiple sclerosis
Sheridan, Cormac
NATURE BIOTECHNOLOGY, 2015, 33 (12) : 1215 - 1216
[5] Measuring CD20 binding for humanization of anti-CD20 antibody
Meng, YJG
Hong, K
Presta, L
Penn, A
Adams, C
Chuntharapai, A
Yang, JH
Lu, YM
Wong, WL
FASEB JOURNAL, 2004, 18 (04): : A59 - A59
[6] Ofatumumab: a novel monoclonal anti-CD20 antibody
Lin, Thomas S.
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2010, 3 : 51 - 59
[7] Anti-CD20 antibody wows in multiple sclerosis
Cormac Sheridan
Nature Biotechnology, 2015, 33 : 1215 - 1216
[8] Anti-CD20 monoclonal antibody/thalidomideMyeloproliferative disorder in an elderly patient (first report with anti-CD20 monoclonal antibody): case report
Reactions Weekly, 2001, 855 (1) : 7 - 7
[9] BLOCKING B-CELLS (ANTI-CD20/ANTI-CD20)
Isenberg, David A.
RHEUMATOLOGY, 2015, 54 : 1 - 1
[10] Anti-CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis
Korhonen, Riku
Moilanen, Eeva
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2010, 106 (01) : 13 - 21

← 1 2 3 4 5 →